Vincent FERT
-
EVP Immuno-Oncology and EU Operations at Veracyte, Inc.
Veracyte
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
As an immunologist, I founded HalioDx in 2014 with my former partners at Ipsogen and Jérôme Galon, a world specialist in cancer immunology. In the summer of 2021, HalioDx joined the Veracyte group.
Veracyte implements a radically new approach to cancer diagnosis based on the analysis of the immune response: by precisely measuring the anti-tumour immune response of patients, we enable doctors to determine the severity of the disease, regardless of the cancer stage or molecular profile. Using this measurement, they should also be able to predict the response to treatment of their patients, including immunotherapies, which are at the core of the MI project.
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
#industrieHave a look on our testimonies
The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.
Julien CARVELLI
AP-HM
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
Emmanuelle CHARAFE-JAUFFRET
AMU, IPC, CRCM
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
Nicolas SCHLEINITZ
AP-HM, AMU
The laboratory's mission therefore reflects that of the Marseille Immunopôle: to lead the development of these innovations, from the initial discovery to the proof of concept in clinical setting.
Florence SABATIER
AMU, AP-HM
your commitment to MI